FRM
ONC

Fox Run Management’s BeOne Medicines Ltd ONC Stock Holding History

Fox Run Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,136
Closed -$607K – 1369
2026
Q1 		$607K Buy
+2,136
New +$691K 0.11% 358
2025
Q4 		– Sell
-2,058
Closed -$701K – 1335
2025
Q3 		$701K Buy
2,058
+8
+0.4% +$2.43K 0.11% 352
2025
Q2 		$496K Buy
+2,050
New +$503K 0.08% 468
2024
Q1 		– Sell
-2,253
Closed -$406K – 1114
2023
Q4 		$406K Buy
+2,253
New +$408K 0.1% 374
2020
Q2 		– Sell
-1,753
Closed -$216K – 326
2020
Q1 		$216K Buy
+1,753
New +$274K 0.51% 72
2018
Q3 		– Sell
-4,902
Closed -$754K – 864
2018
Q2 		$754K Buy
+4,902
New +$874K 0.24% 114

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fox Run Management's ONC Position: Q2 2026 in Review

Fox Run Management sold out of BeOne Medicines Ltd (ONC) in Q2 2026, closing a stake of 2,136 shares — an estimated $607K sold.

Fox Run Management first reported a position in ONC in Q2 2018 and held it in 6 quarters. The position peaked at $754K in Q2 2018. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Fox Run Management reported no remaining BeOne Medicines Ltd position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 2,136 BeOne Medicines Ltd shares in Q2 2026, an estimated $607K.
  • Fox Run Management first reported a position in BeOne Medicines Ltd in Q2 2018 and held it in 6 quarters.
  • Fox Run Management's BeOne Medicines Ltd position peaked at $754K in Q2 2018.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.